new info in half yearly report

Surprised these didn’t warrant a separate announcement.

There’s a few pretty exciting things mentioned:

• Oraline has reached new prototype stage and the prototypes were successful

• The company is exploring genomic and genetic testing using its existing IP

• The company is exploring hand-held electronic drugs testing devices, using its existing IP

As well as the above, the company confirmed it continues to look at other opportunities in therapeutics.
IMO Excellent.